- Gallagher EJ, Zelenko Z, Tobin Hess A, Wener U, Tennagels N, LeRoith D. Non-metabolizable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. 2016 Epub.
- Gallagher EJ, LeRoith D, Stasinopoulos M, Zelenko Z, Shiloach J. Polyol accumulation in muscle and liver in a mouse model of type 2 diabetes. J. Diabetes Complications. 2016 Epub.
- Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol. Rev. 2015 Jul:95(3): 727-48.
- Kumar A, Shiloach J, Betenbaugh MJ, Gallagher EJ. The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice. Nutr. Metab. (Lond). 2015 Mar 8;12:8.
- Rota LM, Albanito L, Shin ME, Goyeneche CL, Shushanov S, Gallgher EJ, LeRoith D, Lazzarino DA, Wood TL. IGF-1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res. 2014 Oct 1;74(14): 5668-79.
- Kumar A, Harrelson T, Lewis Ne, Gallagher EJ, LeRoith D, Shiloach J, Betenbaugh MJ. Multi-tissue computational modeling analyzes pathophysiology of type 2 diabetes in MKR mice. PLoS One. 2014 Jul 16;9(7).
- Vijayakumar A, Buffin NJ, Gallagher EJ, Blank J, Wu Y, Yakar S, LeRoith D. Deletion of growth hormone receptors in postnatal skeletal muscle of male mice does not alter muscle mass and response to pathological injury. Endocrinology. 2013 Oct; 154(10):3776-83.
- Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, Tennagels N, Werner U, LeRoith D. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF1 receptor. Diabetes. 2013 Oct:62(10):3553-60.
- Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, LeRoith D. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocrinol. Relat. Cancer. 2013 May 21;20(3):391-401.
- Gallagher EJ, LeRoith D. Is growth hormone resistance/IFG1 reduction good for you? Cell Metab. 2011 Apr 6;13(4):355-6.